<DOC>
	<DOCNO>NCT00517361</DOCNO>
	<brief_summary>The purpose study determine progression free survival ( PFS ) metastatic ER , PR HER2/neu negative breast cancer combination carboplatin bevacizumab ( Avastin® ) therapy .</brief_summary>
	<brief_title>Phase II Study Carboplatin Bevacizumab ( Avastin ) ER Neg , PR Neg , HER2/Neu Neg Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must pathologically confirm ER , PR HER2/neu negative ( FISH ratio &lt; 2.0 IHC &lt; 1+ ) metastatic breast cancer . Locally advanced recurrent disease also eligible . Patients must measurable disease Patients must receive prior chemotherapy metastatic breast cancer ( include adjuvant therapy ) . Patients &gt; 4 week recent chemotherapy radiation therapy treatment . Age &gt; 18 year ECOG performance status &lt; 1 ( Karnofsky &gt; 80 % ) . Patients must normal organ marrow function define : absolute neutrophil count &gt; 1,500/uL platelet &gt; 100,000/uL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5X institutional upper limit normal creatinine within normal institutional limit OR creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal PT INR &lt; 1.5 ( Unless patient anticoagulation ) urine protein &lt; 1+ Tissue primary tumor must available correlative study Women childbearing potential must agree use adequate contraception Ability understand willingness sign write informed consent document . Patients prior therapy platinum agent VEGF inhibitor eligible . Patients may receive investigational agent . Patients know brain metastasis exclude Patients may prior radiation therapy , provide patient measurable disease clear progression since completion radiation therapy . Patients radiotherapy within 4 week prior enter study recover adverse event due therapy administer 4 week earlier exclude . Patients significant cardiac dysfunction exclude Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study , breastfeed discontinue . HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction carboplatin agent administer study . Patients evidence bleed diathesis coagulopathy . Patients inadequately control hypertension exclude Patients stroke TIA within 6 month registration exclude . Patients history hypertensive crisis hypertensive encephalopathy exclude . Patients history abdominal fistula , GI perforation , intraabdominal abscess within 6 month registration . Patient history serious nonhealing wound , ulcer bone fracture . Patients major surgery , open biopsy , significant traumatic injury within 28 day registration anticipate need surgery course study treatment . Patients history core biopsy minor surgery , exclude venous access device ( VAD ) placement , within 7 day registration . Patients active second malignancy . Known hypersensitivity component bevacizumab ( Avastin® ) . Peripheral neuropathy &gt; Grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>